Search hospitals > Colorado > Boulder
Rocky Mountain Cancer Centers-Boulder
Claim this profileBoulder, Colorado 80304
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Tumors
217 reported clinical trials
9 medical researchers
Summary
Rocky Mountain Cancer Centers-Boulder is a medical facility located in Boulder, Colorado. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Tumors and other specialties. Rocky Mountain Cancer Centers-Boulder is involved with conducting 217 clinical trials across 365 conditions. There are 9 research doctors associated with this hospital, such as Nicholas DiBella, Robert M. Jotte, Sami Diab, and Keren Sturtz.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage II
2Breast Cancer
Global LeaderStage IV
HER2 negative
Stage III
Top PIs
Nicholas DiBellaRocky Mountain Cancer Centers-Boulder5 years of reported clinical research
Expert in Cancer
Expert in Breast Cancer
95 reported clinical trials
180 drugs studied
Robert M. JotteGSK Investigational Site3 years of reported clinical research
Studies Non-Small Cell Lung Cancer
Studies Lung Cancer
6 reported clinical trials
11 drugs studied
Sami DiabRocky Mountain Cancer Centers7 years of reported clinical research
Studies Breast Cancer
Studies Ovarian Cancer
5 reported clinical trials
11 drugs studied
Keren SturtzSCL Health Lutheran Medical Center8 years of reported clinical research
Studies Breast Cancer
Studies Ovarian Cancer
4 reported clinical trials
14 drugs studied
Clinical Trials running at Rocky Mountain Cancer Centers-Boulder
Breast Cancer
Lung Cancer
Cancer
Non-Small Cell Lung Cancer
Prostate Cancer
Bladder Cancer
Melanoma
Cutaneous Melanoma
Follicular Lymphoma
Tumors
Sacituzumab Govitecan
for Triple-Negative Breast Cancer
The primary objective of this study is to compare the progression-free survival (PFS) between sacituzumab govitecan-hziy (SG) versus treatment of physician's choice (TPC) in participants with previously untreated, locally advanced, inoperable or metastatic triple-negative breast cancer whose tumors do not express programmed cell death ligand 1 (PD-L1) or in participants previously treated with anti-programmed cell death (ligand or protein) 1 (Anti-PD-(L)1) Agents in the early setting whose tumors do express PD-L1.
Recruiting4 awards Phase 3
Sacituzumab Govitecan + Pembrolizumab
for Triple-Negative Breast Cancer
The primary objective of this study is to compare the progression-free survival (PFS) between sacituzumab govitecan-hziy (SG) and pembrolizumab versus treatment of physician's choice (TPC) and pembrolizumab in participants with previously untreated, locally advanced inoperable or metastatic triple-negative breast cancer, whose tumors express programmed cell death ligand 1 (PD-L1).
Recruiting4 awards Phase 3
Support Program
for Breast Cancer
This study is evaluating whether a support program may help breast cancer patients take their medication correctly.
Recruiting2 awards Phase 34 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Rocky Mountain Cancer Centers-Boulder?
Rocky Mountain Cancer Centers-Boulder is a medical facility located in Boulder, Colorado. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Tumors and other specialties. Rocky Mountain Cancer Centers-Boulder is involved with conducting 217 clinical trials across 365 conditions. There are 9 research doctors associated with this hospital, such as Nicholas DiBella, Robert M. Jotte, Sami Diab, and Keren Sturtz.